Handbook/Growth Hormone Secretagogues/CJC-1295 5mg + Ipamorelin 5mg

CJC-1295 5mg + Ipamorelin 5mg

Featured

Also known as: CJC/Ipa 5mg Combo, High-Dose GH Stack, GHRH/GHRP 5mg

A higher-dose pre-mixed CJC-1295 and Ipamorelin combination for extended GH protocols.

Overview

This higher-dose combination contains 5mg each of CJC-1295 (no DAC) and Ipamorelin in a single vial. It provides more total peptide for extended protocols or those who prefer fewer reconstitutions. Same synergistic GHRH/GHRP mechanism as standard combo.

Mechanism of Action

CJC-1295 activates GHRH receptors, Ipamorelin activates ghrelin receptors. Together they create amplified, synergistic GH pulses that better mimic natural physiology.

Pharmacokinetics

Same as individual components. More total peptide per vial for extended use or higher dosing preferences.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Standard Protocol

Dose

100-300 mcg each

Frequency

2-3x daily

Duration

12+ weeks

More doses per vial

2

Anti-Aging

Dose

100 mcg each

Frequency

Nightly

Duration

Ongoing

Extended duration per vial

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: 24-hour GH support

Synergy: Oral secretagogue between injections

Research Areas

Growth Hormone OptimizationAnti-AgingBody CompositionRecoveryExtended Protocols

Key Research Findings

  • 1Higher total peptide per vial
  • 2Same synergistic mechanism
  • 3Cost-effective for extended use
  • 4Popular for serious protocols

Side Effects & Contraindications

Reported Side Effects

  • Water retention
  • Tingling
  • Increased hunger (mild)
  • Vivid dreams

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Carpal tunnel

Safety Considerations

Same as standard CJC/Ipa combo. Individual dosing still applies. Monitor for water retention, tingling.

Storage Requirements

Refrigerate 2-8C after reconstitution

Scientific References

Quick Reference

Sequence
Combination product
Molecular Weight
Variable
Half-Life
30 min - 2 hours
Bioavailability
Injectable
Research Stage
clinical phase 2
Administration
Subcutaneous injection